Brief: Appili Therapeutics Announces Over Us$10 Million In New Funding From US Department Of Defense For Biodefense Vaccine Candidate ATI-1701
28/02/2022 13:49
Feb 28 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES OVER US$10 MILLION IN NEW
FUNDING
FROM US DEPARTMENT OF DEFENSE FOR BIODEFENSE VACCINE CANDIDATE
ATI-1701
* APPILI THERAPEUTICS INC- NEW FUNDING IS DESIGNED TO
REPLACE AND
EXPAND UPON PRIOR CONTRACT AWARDED TO ONE OF APPILI'S
DEVELOPMENT PARTNERS
* APPILI THERAPEUTICS INC- APPILI WILL SERVE AS PRIME
CONTRACTOR
AND OVERSEE COMPREHENSIVE DEVELOPMENT PROGRAM FOR ATI-1701
Source text for Eikon: ID:nBw8PnyPa
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez